MDGL

337.61

1.90% 6.29

Handel nachbörslich: 337.61

Madrigal Pharmaceuticals Inc (MDGL)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt MDGL? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$331.32

Offen:

$331

24-Stunden-Volumen:

769.60K

Relative Volume:

2.19

Marktkapitalisierung:

$7.25B

Einnahmen:

Nettoeinkommen (Verlust:

$-510.45M

KGV:

-17.55

EPS:

-19.24

Netto-Cashflow:

$-455.82M

1W Leistung:

+55.02%

1M Leistung:

+61.99%

6M Leistung:

+46.89%

1J Leistung:

+129.84%

1-Tages-Spanne:

$316.67

$337.63

1-Wochen-Bereich:

$213.71

$337.63

52-Wochen-Spanne:

$133.99

$337.63

Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile

Firmenname

Madrigal Pharmaceuticals Inc

Sektor

Healthcare (1182)

Branche

Biotechnology (671)

Telefon

404-380-9263

Adresse

200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA

Mitarbeiter

376

Twitter

@MadrigalPharma

Nächster Verdiensttermin

2024-10-31

Neueste SEC-Einreichungen

MDGL's Discussions on Twitter

Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2022-12-20	Bestätigt	Oppenheimer	Outperform
2022-12-19	Bestätigt	H.C. Wainwright	Buy
2022-12-19	Bestätigt	Piper Sandler	Overweight
2022-12-19	Hochstufung	Raymond James	Underperform → Mkt Perform
2022-07-08	Herabstufung	B. Riley Securities	Buy → Neutral
2021-10-07	Eingeleitet	Jefferies	Buy
2021-08-06	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2021-05-20	Fortgesetzt	Goldman	Buy
2020-11-24	Fortgesetzt	Evercore ISI	Outperform
2020-11-06	Bestätigt	H.C. Wainwright	Buy
2020-07-31	Eingeleitet	Piper Sandler	Overweight
2020-06-05	Eingeleitet	BMO Capital Markets	Market Perform
2020-05-05	Eingeleitet	Chardan Capital Markets	Buy
2020-01-30	Eingeleitet	Canaccord Genuity	Buy
2020-01-09	Hochstufung	UBS	Neutral → Buy
2019-11-07	Bestätigt	H.C. Wainwright	Buy
2019-06-25	Eingeleitet	Stifel	Hold
2019-06-10	Hochstufung	B. Riley FBR	Neutral → Buy
2019-02-28	Bestätigt	H.C. Wainwright	Buy
2019-02-22	Eingeleitet	SVB Leerink	Outperform
2019-01-23	Eingeleitet	UBS	Neutral
2018-12-14	Eingeleitet	Wolfe Research	Outperform
2018-12-12	Eingeleitet	B. Riley FBR	Neutral
2018-11-19	Herabstufung	Raymond James	Mkt Perform → Underperform
2018-11-16	Hochstufung	Evercore ISI	In-line → Outperform
2018-09-04	Eingeleitet	Citigroup	Buy
2018-08-06	Herabstufung	Goldman	Buy → Neutral
2018-06-28	Eingeleitet	Raymond James	Mkt Perform

Alle ansehen

Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten

11:35 AM

B. Riley Forecasts Strong Price Appreciation for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock - MarketBeat

11:35 AM

Nov 04, 2024

Check Out What Whales Are Doing With MDGL - Benzinga

Nov 04, 2024

Madrigal Pharmaceuticals (NASDAQ:MDGL) Sets New 1-Year High on Analyst Upgrade - MarketBeat

Nov 04, 2024

Madrigal Stock Soars 23% as NASH Drug Rezdiffra Crushes Expectations - Yahoo Finance

Nov 04, 2024

What is Leerink Partnrs' Forecast for MDGL FY2028 Earnings? - MarketBeat

Nov 04, 2024

Emerald Advisers LLC Has $5.79 Million Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat

Nov 04, 2024

Nov 03, 2024

Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio? - Benzinga

Nov 03, 2024

Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion - Seeking Alpha

Nov 03, 2024

Nov 02, 2024

(MDGL) Long Term Investment Analysis - Stock Traders Daily

Nov 02, 2024

Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH - Yahoo Finance

Nov 02, 2024

Forecast: Analysts Think Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Business Prospects Have Improved Drastically - Simply Wall St

Nov 02, 2024

Analysts Just Made A Notable Upgrade To Their Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Forecasts - Yahoo Finance

Nov 02, 2024

Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up - MSN

Nov 02, 2024

Madrigal Pharmaceuticals Announces Strong Q3 2024 Results and Strategic Advances - MSN

Nov 02, 2024

Nov 01, 2024

MDGL stock soars to 52-week high, reaching $299.99 By Investing.com - Investing.com South Africa

Nov 01, 2024

Madrigal Pharma Stock Soars Despite Novo Nordisk’s ‘Superior’ MASH Trial Results: Retail Bullish On Earnings Beat - MSN

Nov 01, 2024

Novo's Wegovy Isn't A 'Silver Bullet' For MASH. Madrigal Rockets. - Investor's Business Daily

Nov 01, 2024

Madrigal Pharmaceuticals stock jumps on MASH drug hopes - Yahoo Finance

Nov 01, 2024

Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Raised to $441.00 at UBS Group - MarketBeat

Nov 01, 2024

Madrigal Pharmaceuticals (NASDAQ:MDGL) Posts Earnings Results, Beats Estimates By $2.02 EPS - MarketBeat

Nov 01, 2024

MDGL stock soars to 52-week high, reaching $299.99 - Investing.com

Nov 01, 2024

Madrigal Pharmaceuticals (NASDAQ:MDGL) Sees Strong Trading Volume After Strong Earnings - MarketBeat

Nov 01, 2024

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q3 2024 Earnings Call Transcript - MSN

Nov 01, 2024

Regeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drug - Yahoo Finance

Nov 01, 2024